Chemoradiotherapy followed by Chemotherapy and Dostarlimab for the Treatment of Stage IIIC Endometrial Cancer

Inclusion Criteria

• Has read and understands the informed consent form (ICF) and has given written informed consent prior to any study procedures
• Have surgically staged IIIC, pathologically confirmed endometrial cancer of any histologic subtype and be eligible for adjuvant chemoradiation followed by chemotherapy (Note: Surgical staging is defined as total hysterectomy and lymph node assessment.)
• Enrolled within 8 weeks of surgery and started treatment within 10 weeks of surgery
• Age >= 18 years
• Performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1
• Hemoglobin >= 9 g/dL (within 14 days prior to enrollment)
• Platelets >= 100,000/mcl (within 14 days prior to enrollment)
• Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to enrollment)
• Creatinine =< 2 x laboratory upper limit of normal (ULN) or creatinine clearance (CrCl) >= 60ml/min (within 14 days prior to enrollment)
• Bilirubin =< 1.5 x ULN (patients with known Gilbert’s disease who have bilirubin level =< 2 x ULN may be enrolled) (within 14 days prior to enrollment)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (within 14 days prior to enrollment)
• International normalized ratio (INR) or prothrombin time (PT)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 14 days prior to enrollment)
• Prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial (i.e. non melanomatous skin cancer).

Exclusion Criteria

• Has not recovered (i.e., to grade =< 1 or to baseline) from prior radiation, major surgery and chemotherapy-induced adverse events (AEs)
• Surgery =< 3 weeks prior to initiating protocol therapy investigational therapy =< 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is shorter, prior to initiating protocol therapy
• Has received prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or other similar agents
• Has a history of a severe hypersensitivity reaction to monoclonal antibody or dostarlimab and/or its excipients
• Have active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. This includes, but is not limited to: a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain- Barre syndrome, myasthenia gravis, systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn’s, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome because of the risk of recurrence or exacerbation of disease
• History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies
• Have a diagnosis of immunodeficiency or are receiving daily systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to enrollment: * Steroids received as CT scan contrast premedication may be enrolled. * The use of inhaled or topical corticosteroids is allowed. * The use of mineralocorticoids (e.g., fludrocortisone) for orthostatic hypotension or adrenocortical insufficiency is allowed. * The use of physiologic doses of corticosteroids may be allowed and in consultation with the study chair (e.g. 10 mg of prednisone used for replacement therapy for adrenal insufficiency)
• Have received a live vaccine within 30 days of starting trial therapy
• Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; and cirrhosis. * Evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load, tested positive for the presence of hepatitis B surface antigen, or have a positive hepatitis C antibody test result at screening or within 3 months prior to the first dose of study treatment
• Uncontrolled intercurrent illness including (but not limited to): ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Have received any of the prohibited medications
• Has leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastases, or radiologic signs of central nervous system (CNS) hemorrhage. Note: Asymptomatic brain metastases (i.e, off corticosteroids and anticonvulsants for at least 7 days) are permitted
• Known human immunodeficiency virus (HIV)-infected patients
• Women of childbearing potential (WoCBP) who have been not been permanently or surgically sterilized and are capable of procreation